Breaking News


Boehringer’s BIBF 1120 as Effective as Bevacizumab in Patients

Boehringer Ingelheim’s BIBF 1120 in patients with metastatic colorectal cancer is as effective as bevacizumab with less serious adverse events, results from a Phase I/II study showed, the company said in an e-mailed statement today.

To contact the editor responsible for this story: Rajiv Sekhri at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.